LIDDS Delårsrapport januari – september 2020
November 19, 2020 02:45 ET
|
LIDDS AB
JANUARI – SEPTEMBER 2020 Nettoomsättningen uppgick till MSEK 0,0 (0,0)Rörelsens kostnader uppgick till MSEK -19,8 (-22,9)Resultatet före och efter skatt uppgick till MSEK -19,8 (-22,9)Resultat per...
A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development
November 18, 2020 09:15 ET
|
LIDDS AB
A scientific review article “Toll-Like Receptor 9 Agonists in Cancer”, written by Dr Davar Diwakar et al, a prominent immune-oncology research group in Pittsburgh (US), was recently published in the...
LIDDS' NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect
October 26, 2020 03:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announces that intratumoral injection of NZ-TLR9, NanoZolid (NZ) formulation of a Toll-Like Receptor 9 (TLR9), results in strong antitumoral efficacy combined with...
LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020
October 19, 2020 03:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) ("LIDDS" or the "Company") announced today the outcome of the subscription of shares in the incentive programs 2017/2020. Last day of subscription was on October 15,...
LIDDS Announces Data on Liproca Depot from Open Label Extension Study
September 30, 2020 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 %...
LIDDS Delårsrapport januari – juni 2020
August 20, 2020 02:45 ET
|
LIDDS AB
APRIL – JUNI 2020 Nettoomsättningen uppgick till MSEK 0,0 (0,0)Rörelsens kostnader uppgick till MSEK –5,3 (-8,4)Resultatet före och efter skatt uppgick till MSEK -5,3 (-8,4)Resultat per aktie...
LIDDS licensee, Puheng Pharma, evaluates a novel expeditated regulatory path for Liproca Depot in China
August 20, 2020 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announces that its licensee Jiangxi Puheng Pharma is currently preparing documentation for an application targeting a newly issued regulatory guideline in China on...
LIDDS företrädesemission kraftigt övertecknad
July 09, 2020 02:30 ET
|
LIDDS AB
LIDDS AB ("LIDDS" eller "Bolaget") offentliggjorde den 11 juni 2020 att styrelsen, med stöd av årsstämmans bemyndigande, beslutat att genomföra en nyemission med företrädesrätt för befintliga...
LIDDS publishes the outcome in the Share Issues
July 09, 2020 02:30 ET
|
LIDDS AB
LIDDS AB (“LIDDS” or the “Company”) announced on 11 June 2020 that the Board of Directors, pursuant to the authorization granted by the annual general meeting, has resolved to carry out a new...
LIDDS publishes prospectus in connection with forthcoming rights issue
June 17, 2020 02:45 ET
|
LIDDS AB
LIDDS AB (“LIDDS” or the “Company”) announced on 11 June 2020 that the Board of Directors, pursuant to the authorization granted by the annual general meeting, has resolved to carry out, inter alia, a...